John Guandolo leverages his experience as a former FBI Special Agent and retired U.S. Marine Corps officer to provide threat-focused training for various entities as the founder of UnderstandingTheThreat.com. On top of his professional pursuits, John Guandolo supports several charities and organizations, including the National Multiple Sclerosis (MS) Society.
According to a recent press release from the National MS Society, the MS Outcome Assessments Consortium (MSOAC), a global initiative supported by the National MS Society, held its third annual workshop in March. The event highlighted significant progress on the creation of a new tool expected to provide a more sensitive method of detecting the advantages of different treatments that reduce or reverse increasing disability for individuals with MS. The workshop, which took place in Washington, DC, brought together representatives from a number of major organizations, including the U.S. Food and Drug Administration (FDA), the National Institutes of Health, and the European Medicines Agency (EMA).
The MSOAC has been busy amassing data from a wide range of MS clinical trials that will eventually be analyzed to inform the optimal outcome measures for integration in the new tool. By the end of the four-year project, the consortium will submit the proposed tool to the EMA and FDA for approval as a primary outcome measure in clinical MS trials.